Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians
Version:
1
Apr 2023
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Guideline Objective
To provide clinicians with guidance on implementation of routine, pre-treatment DPYD testing and genotype-guided dosing for cancer patients with planned fluoropyrimidine treatment in Ontario.
Patient Population
Cancer patients who are candidates for systemic treatment with fluoropyrimidines (5-fluorouracil or capecitabine)
Intended Guideline Users
Health care providers involved in the care of cancer patients who have planned systemic treatment with fluoropyrimidines (medical oncologists, nurses, pharmacists)
Summary (PDF) (275.63 KB)
Full Report (PDF) (453.18 KB)